Bone mineral density of the proximal tibia following uncemented arthroplasty

Bone mineral density (BMD, g/cm2) was measured using dual-photon absorptiometry (DPA) in selected areas of the proximal tibia following uncemented PCA knee prosthesis. In nine patients with 14 alloplastic operations, measurements were taken at 3-6-month intervals for the first 3 1/2 years after operation. There was a significant increase in BMD of about 15% during the first 6 months after operation. The following year it remained increased, although not significantly, compared with the initial values, then gradually diminished. Increased bone density after arthroplasty may be explained mainly by stimulation of bone formation from weight bearing due to improved walking ability. Stress shielding of the proximal part of the supporting tibial bone did not seem to occur.     

关注IHE关键影像标记在PACS中的应用

关键影像标记通过指定一组事务处理的定义,将影像检查序列中一帧或多帧关键影像与其对应的注释信息进行关联。本文对该集成模型的角色、事务处理以及相关的DICOM内容进行了分析。     

Treatment of osteoporosis in men

Osteoporosis in men is recognised worldwide as an important and increasing public health problem. The causes are more heterogeneous than those in women. About 50% are diagnosed as secondary cases. In some secondary forms of osteoporosis the specific diagnosis results in additional therapeutic options (e.g. androgen therapy in proven hypogonadism). The basic therapy for osteoporosis in men is no different to that in postmenopausal women, namely recommendations for counteracting modifiable risk factors, especially with regard to diet, physical exercise, and calcium and vitamin D supplementation. Concerning specific drug medications, however, even today there is still a therapeutic dilemma in male osteoporosis. While older substances (e.g. calcitonin, fluoride, alfacalcidol) are approved for both sexes, all newer medications have primarily been approved for the treatment of postmenopausal osteoporosis. Health authorities request studies in purely male populations. For new drugs, fracture data are necessary while for new substances within a class (e.g. bisphosphonates), at the very least consistent effects on bone mineral density (BMD) and bone turnover markers are requested. Due to these regulatory rules, ibandronate, teriparatide and strontium ranelate are not approved in the European Union. Some years ago, alendronate was the first bisphosphonate that was approved for the treatment of men with osteoporosis, based on consistent results from two independent male studies using a daily 10 mg dosage. Very recently risedronate was approved by the FDA and EMEA. A randomised, placebo-controlled multicentre trial of 285 male patients showed, after 2 years, a 5.8% increase in lumbar spine BMD in the risedronate 35 mg once weekly group vs 1.2% in the placebo group. In a prospective controlled study on 316 men with primary or secondary osteoporosis we found, after 12 months, a lumbar spine BMD of +4.7% vs +1.0% in controls. The number of patients with one or more new vertebral fractures was 8 in the risedronate group and 20 in the placebo group (a fracture reduction of 60%). Furthermore, we found a significantly smaller decrease in height and a steeper decrease in back pain in the risedronate group. Risedronate is the first oral bisphosphonate available for men with the more comfortable once weekly dosage.     

不同类型正常乳腺表观扩散系数值差异的研究

目的 研究不同类型正常乳腺表观扩散系数（ADC）值的差异，探讨ADC值与组织学分型之间的关系。方法 采用单次激发平面回波（EPI）技术，扩散敏感因子（b）值分别为0、500、1000s／mm^2，对62个正常乳腺（包括42例乳腺病变患者的对侧正常乳腺及10名健康志愿者20个乳腺）进行MR扫描及MR扩散加权成像（DWI）检查，计算62个正常乳腺分别在不同b值时的ADC值。将62个正常乳腺分为3型，比较3型之间ADC值的差异及不同b值时ADC值的差异。结果 42例乳腺病变患者对侧正常乳腺的DWI及ADC图与组织切片对比，不同类型乳腺组织学结构不同，其DWI及ADC图表现亦有差异。62个正常乳腺分为致密型10个，分叶斑点型42个及退化型10个。致密型和分叶斑点型乳腺随b值降低ADC值升高，而退化型乳腺随b值降低ADC值变化不明显。b=1000—0s／mm^2时，致密型、分叶斑点型、退化型乳腺ADC值分别为（1．70±0．37）、（1．93±0．46）、（1．18±0．65）×10^-3mm^2／s，3组间比较差异有统计学意义（F=12．998，P=0．000）。不同b值时每2种类型间进行单因素方差分析，致密型和分叶斑点型之间差异无统计学意义（F=2．167，P=0．147）；致密型和退化型之间、分叶斑点型和退化型之间差异均有统计学意义（F值分别为5．593、19．128，P值分别为0．029、0．000）。结论 3型正常乳腺ADC值受乳腺组织学结构的影响，致密型和分叶斑点型乳腺ADC值受b值高低的影响。     

一种简单实用的测量气管截面积的方法

目的介绍一种简单实用而较精确的测量狭窄气管截面积的方法.方法利用纤维支气管镜、测长器、模拟气管等制作并校正测量标尺,并利用该标尺测量了3例气管状况异常患者的气管某一截面面积.结果用校正过的4种测量标尺测量了10个模拟气管的直径,和实测真值比较经t检验分析无显著性差异,利用上述标尺测量的3个患者的目的截面面积分别为约96 mm2、 105 mm2和192 mm2.结论本方法提供了一种简单、快速而又较精确的测量大气道某一截面面积的方法,为定量评价患者的通气功能、选择气管支架或采用其他干预手段处理气管病变提供了数据参考.     

过氧化物酶体增殖物激活受体γC161T基因多态性与糖皮质激素性骨质疏松症的关系

目的 探讨中国人过氧化物酶体增殖物激活受体γ(PPARγ)基因外显子6 C161T多态性与糖皮质激素性骨质疏松症(GIO)的相关关系。方法 应用聚合酶链反应-限制性片段长度多态性(PCR-RELP)方法测定208例正常健康人（Ⅰ组）、168例非GIO患者（Ⅱ组）和104例GIO患者（Ⅲ组）PPARγ基因外显子6 C161T的基因型。应用双能X线骨密度仪(DEXA)测定股骨、腰椎等部位的骨密度。 结果 外显子6 C161T有CC、CT、TT 3种基因型。GIO组CC基因型频率显著低于正常对照组；CT和TT基因型频率显著高于正常对照组。非GIO组、应用激素组（GIO组＋非GIO组）与正常对照组比较，各基因型频率差异均无统计学意义。正常对照组C161T的CC基因型组各部位的骨密度有高于CT和TT基因型组的趋势，但差异无统计学意义。非GIO组和GIO组C161T的CC基因型组腰椎的骨密度明显高于CT和TT基因型组 (P ＜ 0.05)，分别为非GIO组CC型（1.04±0.17） g/cm2，CT+TT型（1.02±0.07） g/cm2；GIO组CC型（0.94±0.12） g/cm2，CT+TT型（0.83±0.08） g/cm2。经年龄、体重指数等因素校正后，差异仍有统计学意义(P ＜ 0.05）。 结论 PPARγ基因C161T基因型在正常人和应用激素患者之间无明显差异，它可能与肾小球肾炎的发病无关。C161T基因型在GIO组和正常对照组之间差异有统计学意义，它可能与糖皮质激素性骨质疏松症的发病有关。PPARγ基因C161T多态性与应用糖皮质激素患者腰椎的骨密度有关。等位基因C可能是骨量的保护因子，它可能与应用糖皮质激素后骨量的丢失有关。     

乳腺癌新辅助化疗后动态增强MRI表现与病理反应性相关性研究

目的探讨乳腺癌新辅助化疗后动态增强MRI（DCE—MRI）表现的形态学和时间信号强度曲线（TIC）类型与病理学反应性的关系。方法45例乳腺癌患者经新辅助化疗结束后行乳腺DCE—MR检查及手术治疗。应用AW4．2图像工作站观察残余肿瘤强化的形态和TIC类型（共3型）。由病理科医师对乳腺癌化疗后手术标本的病理反应性进行评估，分为1～5级，5级为病理完全缓解，4级和5级为组织学显著反应。分析病理反应性级别与DCE—MRI残余强化的TIC类型、形态的关系，统计方法采用精确概率法。结果45例中病理反应性5级7例，4级16例，3级16例，1和2级共6例。20例I型曲线中组织学显著反应者占70．0％（14／20），而6例Ⅲ型曲线均为组织学反应不显著者。TIC类型在不同的病理反应级别分布差异有统计学意义（P=0．001）。组织学显著反应且有残余强化者共18例，其中非肿块性强化11例。残余强化的肿块（非肿块）形态表现在不同病理反应性分级中分布差异有统计学意义（P=0．012）。结论乳腺癌新辅助化疗后DCE—MRI的形态及血液动力学表现特点与化疗后病理反应性相关。非肿块性强化和I型TIC与组织学显著反应有关。     

老年冠心病患者止凝血功能与血脂的关系

目的探讨止凝血功能和血脂对老年冠心病患者发病的作用及其关系。方法采用ELISA法测定250例冠心病患者和80例对照者的凝血酶-抗凝血酶Ⅲ复合物(TAT)、血浆血管性血友病因子抗原(vWF:Ag)、P-选择素(P-selectin)、D-二聚体(D-D)水平,以Clauss法测定血浆纤维蛋白原(FG)水平,双抗体酶联免疫吸附法测定血浆Lp(a)浓度,并检测血清TC、TG、LDL-C、HDL-C水平。结果冠心病组血浆FG、TAT、vWF:Ag、P-selectin、D-D及血脂水平明显高于对照组(P<0.05);随着冠状动脉病变支数增加,除HDL-C逐渐降低外,其余指标均明显升高(P<0.05)。FG、LDL-C、Lp(α)与冠状动脉病变程度密切相关(P<0.05),且LDL-C、Lp(α)与FG水平相关。结论FG、LDL-C、Lp(α)是冠心病发病的独立危险因子,对冠心病发生和发展起协同促进作用;血浆FG、TAT、vWF:Ag、P-selectin、D-D浓度的动态连续监测对体内高凝状态和冠心病预防具重要意义;临床抗凝和降纤治疗与降脂治疗宜同时进行。     

体表面积、体质量指数对老年骨质疏松的影响

目的探讨体表面积（BS）、体质量、体质量指数（BMI）对老年人骨密度（BMD）的影响。方法用双能X线骨密度仪测定1794例老年人腰椎、髋关节的BMD值，并对其与BS等指标进行相关回归分析。结果BS大的老年人其BMD大于BS小者，有显著性差异。在各种指标与BMD的相关性比较中，BS与BMD的相关性最好，其后依次为：体质量、身高、OSTA得分（亚洲人自我骨质疏松筛查工具）、BMI。结论BS比BMI等指标更能反映出人体体型对老年人BMD的影响。